1/30/2012

Patients with moderate to severe type 1 diabetes showed improvements in fasting C-peptide levels and significant reductions in HbA1C rates and insulin doses 12 and 24 weeks after treatment with cord blood stem cells, researchers reported in BMC Medicine.

Full Story:
Endocrine Today

Related Summaries